These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 31005427)
1. Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1. Gränicher G; Coronel J; Pralow A; Marichal-Gallardo P; Wolff M; Rapp E; Karlas A; Sandig V; Genzel Y; Reichl U Vaccine; 2019 Nov; 37(47):7019-7028. PubMed ID: 31005427 [TBL] [Abstract][Full Text] [Related]
2. Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems. Coronel J; Behrendt I; Bürgin T; Anderlei T; Sandig V; Reichl U; Genzel Y Vaccine; 2019 Nov; 37(47):7011-7018. PubMed ID: 31266669 [TBL] [Abstract][Full Text] [Related]
3. Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production. Bissinger T; Fritsch J; Mihut A; Wu Y; Liu X; Genzel Y; Tan WS; Reichl U Vaccine; 2019 Nov; 37(47):7003-7010. PubMed ID: 31047676 [TBL] [Abstract][Full Text] [Related]
4. Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the "von Magnus effect". Tapia F; Wohlfarth D; Sandig V; Jordan I; Genzel Y; Reichl U PLoS One; 2019; 14(11):e0224317. PubMed ID: 31689309 [TBL] [Abstract][Full Text] [Related]
5. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003 [TBL] [Abstract][Full Text] [Related]
6. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor. Tapia F; Vogel T; Genzel Y; Behrendt I; Hirschel M; Gangemi JD; Reichl U Vaccine; 2014 Feb; 32(8):1003-11. PubMed ID: 24269322 [TBL] [Abstract][Full Text] [Related]
7. Serum-Free Suspension Culture of MDCK Cells for Production of Influenza H1N1 Vaccines. Huang D; Peng WJ; Ye Q; Liu XP; Zhao L; Fan L; Xia-Hou K; Jia HJ; Luo J; Zhou LT; Li BB; Wang SL; Xu WT; Chen Z; Tan WS PLoS One; 2015; 10(11):e0141686. PubMed ID: 26540170 [TBL] [Abstract][Full Text] [Related]
8. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17. Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695 [TBL] [Abstract][Full Text] [Related]
9. High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells. Wu Y; Bissinger T; Genzel Y; Liu X; Reichl U; Tan WS Appl Microbiol Biotechnol; 2021 Feb; 105(4):1421-1434. PubMed ID: 33515287 [TBL] [Abstract][Full Text] [Related]
10. Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line. Peschel B; Frentzel S; Laske T; Genzel Y; Reichl U Vaccine; 2013 Nov; 31(48):5693-9. PubMed ID: 24113260 [TBL] [Abstract][Full Text] [Related]
11. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Genzel Y; Dietzsch C; Rapp E; Schwarzer J; Reichl U Appl Microbiol Biotechnol; 2010 Sep; 88(2):461-75. PubMed ID: 20617311 [TBL] [Abstract][Full Text] [Related]
12. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines. Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718 [TBL] [Abstract][Full Text] [Related]
13. Mathematical model of influenza A virus production in large-scale microcarrier culture. Möhler L; Flockerzi D; Sann H; Reichl U Biotechnol Bioeng; 2005 Apr; 90(1):46-58. PubMed ID: 15736163 [TBL] [Abstract][Full Text] [Related]
14. Perfusion Control for High Cell Density Cultivation and Viral Vaccine Production. Nikolay A; Bissinger T; Gränicher G; Wu Y; Genzel Y; Reichl U Methods Mol Biol; 2020; 2095():141-168. PubMed ID: 31858467 [TBL] [Abstract][Full Text] [Related]
15. High-cell-density cultivations to increase MVA virus production. Vázquez-Ramírez D; Genzel Y; Jordan I; Sandig V; Reichl U Vaccine; 2018 May; 36(22):3124-3133. PubMed ID: 29433897 [TBL] [Abstract][Full Text] [Related]
16. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system. Vázquez-Ramírez D; Jordan I; Sandig V; Genzel Y; Reichl U Appl Microbiol Biotechnol; 2019 Apr; 103(7):3025-3035. PubMed ID: 30796494 [TBL] [Abstract][Full Text] [Related]
17. Performance of an acoustic settler versus a hollow fiber-based ATF technology for influenza virus production in perfusion. Gränicher G; Coronel J; Trampler F; Jordan I; Genzel Y; Reichl U Appl Microbiol Biotechnol; 2020 Jun; 104(11):4877-4888. PubMed ID: 32291490 [TBL] [Abstract][Full Text] [Related]
18. Development of suspension adapted Vero cell culture process technology for production of viral vaccines. Shen CF; Guilbault C; Li X; Elahi SM; Ansorge S; Kamen A; Gilbert R Vaccine; 2019 Nov; 37(47):6996-7002. PubMed ID: 31288997 [TBL] [Abstract][Full Text] [Related]
19. [Adherent and single-cell suspension culture of Madin-Darby canine kidney cells in serum-free medium]. Huang D; Zhao L; Tan W Sheng Wu Gong Cheng Xue Bao; 2011 Apr; 27(4):645-52. PubMed ID: 21848001 [TBL] [Abstract][Full Text] [Related]
20. Impact of cultivation conditions on N-glycosylation of influenza virus a hemagglutinin produced in MDCK cell culture. Rödig JV; Rapp E; Bohne J; Kampe M; Kaffka H; Bock A; Genzel Y; Reichl U Biotechnol Bioeng; 2013 Jun; 110(6):1691-703. PubMed ID: 23297157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]